Regulatory Effects of TNFSF15 Gene Polymorphisms on Th17 in Graves' ophthalmopathy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023032

Enrollment

Unknown

Registered

2019-05-08

Start date

2019-05-07

Completion date

Unknown

Last updated

2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' ophthalmopathy

Interventions

Graves disease group without GO:Nil

Graves' ophthalmopathy group:Nil

Control group:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Patients clinically diagnosed as Graves disease or Graves' ophthalmopathy; Healthy controls wrih normal thyroid function and thyroid autoantibodies. ? Can understand the purpose of clinical trials, be a volunteer to participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: ? Pituitary, hypothalamic diseases; ? Conmbined with other endocrine and other autoimmune diseases; ? Patients with severe physical diseases; ? Pregnant and lactating women; ? The suspected cases; ? Pepole with blood phobia.

Design outcomes

Primary

Measure	Time frame
Genetic markers;Cytokine;mRNA;Immune-related factor;DNA methylation;Non-coding RNA;Copy number variations;thyroxin;thyroid stimulating hormone;Thyrotropin receptor antibody;Thyroglobulin antibody;Thyroid peroxidase antibody;Immune cell ratio detection;neutrophil;lymphocyte;platelet;C-reactin protein;	—

Countries

China

Contacts

Public ContactLi Hua

The Yongchuan Hospital of Chongqing Medical University

lihua80@yeah.net+86 15086951976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026